Advaxis, Inc.

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Completed	Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma	Phase 1 / Phase 2	2019-02-12
Withdrawn	A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavir Carcinoma, Non-Small-Cell Lung	Phase 2	2018-12-01
Terminated	A Study of ADXS-NEO Expressing Personalized Tumor Antigens Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer	Phase 1	2018-03-28
Completed	A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal Anal Cancer, Rectal Cancer	Phase 2	2016-06-02
Terminated	Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer High Risk Cervical Cancer, Advanced Cervical Cancer	Phase 3	2015-12-15
Completed	Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors HER2 Expressing Solid Tumors	Phase 1 / Phase 2	2015-09-01
Completed	ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metas Cancer, Prostate Cancer	Phase 1 / Phase 2	2015-06-04
Terminated	A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cervical Cancer, Cancer, Head and Neck Cancer	Phase 1 / Phase 2	2015-04-01
Completed	Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma	Phase 1	2015-03-04
Terminated	An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ Cervical Intraepithelial Neoplasia	Phase 2	2010-04-01